scholarly article | Q13442814 |
P50 | author | Stephen G. Ellis | Q62496584 |
Jeffrey Popma | Q87844791 | ||
Gregg W Stone | Q90754539 | ||
Douglas Spriggs | Q114292220 | ||
Joerg Koglin | Q114321707 | ||
J Tift Mann | Q114444150 | ||
Samuel DeMaio | Q114445138 | ||
P2093 | author name string | Mary E Russell | |
Louis Cannon | |||
Charles D O'Shaughnessy | |||
Patrick Hall | |||
Joel D Greenberg | |||
TAXUS V Investigators | |||
P433 | issue | 10 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | coronary artery disease | Q844935 |
P304 | page(s) | 1215-1223 | |
P577 | publication date | 2005-09-01 | |
P1433 | published in | The Journal of the American Medical Association | Q1470970 |
P1476 | title | Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. | |
P478 | volume | 294 |
Q37438436 | A Comparison of Peri-Procedural Myocardial Infarction between Paclitaxel-Coated Balloon and Drug-Eluting Stent on De Novo Coronary Lesions. |
Q37385456 | A comparison of bare-metal and drug-eluting stents for off-label indications |
Q47161708 | A comparison of the main outcomes from BP-BES and DP-DES at five years of follow-up: A systematic review and meta-analysis |
Q36954581 | A novel platinum chromium everolimus-eluting stent for the treatment of coronary artery disease |
Q33677854 | A prospective evaluation of the safety and efficacy of the TAXUS Element paclitaxel-eluting coronary stent system for the treatment of de novo coronary artery lesions: design and statistical methods of the PERSEUS clinical program |
Q55424383 | A rare complication of percutaneous coronary intervention: Coronary pseudoaneurysm formation. |
Q36680683 | Adjunctive pharmacotherapy for coronary interventions-time to read the writing on the wall |
Q36614126 | An overview of the TAXUS Express, paclitaxel-eluting stent clinical trial program |
Q35670480 | Analysis of potential cost-savings after introduction of drug-eluting balloon angioplasty for in-stent restenosis or small vessel disease |
Q37435155 | Angiographic results of the cobalt chromium Vision and Mini-Vision stents |
Q93379484 | Antiplatelet agents in uncertain clinical scenarios-a bleeding nightmare |
Q34731151 | Are "treatment" bare metal stents superior to "control" bare metal stents? A meta-analytic approach |
Q37458616 | Automated surveillance to detect postprocedure safety signals of approved cardiovascular devices |
Q85555592 | Bare Metal Stents Versus Drug Eluting Stents: Where Do We Stand in 2015? |
Q33833003 | Bayesian design of noninferiority trials for medical devices using historical data |
Q44995869 | Biofunctionalization of titanium surface with multilayer films modified by heparin-VEGF-fibronectin complex to improve endothelial cell proliferation and blood compatibility |
Q47296986 | Blinded sample size recalculation in clinical trials with binary composite endpoints |
Q58752931 | Cardiovascular stents: overview, evolution, and next generation |
Q36940822 | Characterizing the spectrum of in-stent restenosis: implications for contemporary treatment |
Q46944476 | Chronic kidney disease and the risk of stent thrombosis after percutaneous coronary intervention with drug-eluting stents |
Q33770283 | Clinical Implication of Optical Coherence Tomography-Based Neoatherosclerosis |
Q35146546 | Clinical and angiographic outcomes after intracoronary bare-metal stenting |
Q43015474 | Clinical and angiographic outcomes of drug-eluting stents in patients with large vessel and single coronary artery lesion. |
Q38265084 | Clinical outcome of drug-eluting versus bare-metal stents in patients with calcified coronary lesions: a meta-analysis |
Q35579187 | Clinical performance of biodegradable versus permanent polymer drug-eluting stents: A meta-analysis of randomized clinical trials at long-term follow-up |
Q46090522 | Comparable clinical safety and efficacy of biodegradable versus durable polymer paclitaxel eluting stents despite shorter dual antiplatelet therapy: insights from a multicenter, propensity score-matched registry |
Q28551554 | Comparing the Clinical Outcomes between Drug Eluting Stents and Bare Metal Stents in Patients with Insulin-Treated Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 10 Randomized Controlled Trials |
Q33661362 | Comparison of Drug-Eluting Balloon Followed by Bare Metal Stent with Drug-Eluting Stent for Treatment of de Novo Lesions: Randomized, Controlled, Single-Center Clinical Trial. |
Q51679181 | Comparison of Long-Term Outcomes in Real-World Patients Between Resolute Zotarilumus-Eluting and Paclitaxel-Eluting Stents in Small Vessel. |
Q36687927 | Comparison of a drug-eluting balloon first and then bare metal stent with a drug-eluting stent for treatment of de novo lesions: study protocol of a randomized controlled trial |
Q44206351 | Comparison of drug-eluting and bare metal stents in large coronary arteries: findings from the NHLBI dynamic registry |
Q43235841 | Comparison of long-term outcomes following sirolimus-eluting stent vs paclitaxel-eluting stent implantation in patients with long calcified coronary lesions |
Q39717689 | Comparison of long-term outcomes of bare-metal and paclitaxel-eluting stents in New York |
Q51097849 | Comparison of the slow-release polymer-based paclitaxel-eluting Taxus-Express stent with the bare-metal Express stent for saphenous vein graft interventions. |
Q64242473 | Contemporary Management of Stent Failure: Part One |
Q38079934 | Controversies in the use & implementation of drug-eluting stent technology. |
Q33718126 | Coronary Aneurysm Formation After Bioresorbable Vascular Scaffold Implantation Resulting in Acute Myocardial Infarction |
Q41057555 | Coronary stents and vascular response to implantation: literature review |
Q83477274 | Cost-effectiveness of paclitaxel-coated balloon angioplasty and paclitaxel-eluting stent implantation for treatment of coronary in-stent restenosis in patients with stable coronary artery disease |
Q43725719 | Cost-effectiveness of paclitaxel-coated balloon angioplasty in patients with drug-eluting stent restenosis. |
Q55005923 | Current Management of In-Stent Restenosis. |
Q38224405 | Current and future perspectives on drug-eluting bioresorbable coronary scaffolds |
Q37558450 | Current issues in coronary stent technology |
Q37799356 | Current status of the Xience V® everolimus-eluting coronary stent system. |
Q37952250 | Current status, challenges and future directions of drug-eluting balloons |
Q36654328 | Cypher versus Taxus: the stent war. |
Q36968009 | Delivery of large biopharmaceuticals from cardiovascular stents: a review |
Q46030040 | Development of biodegradable drug releasing polymeric cardiovascular stents and in vitro evaluation. |
Q50919067 | Discrepancy between computed tomography coronary angiography and selective coronary angiography in the pre-stenting assessment of coronary lesion length. |
Q36282710 | Drug eluting stents: an updated meta-analysis of randomised controlled trials |
Q38028877 | Drug-coated balloons for coronary and peripheral interventional procedures |
Q38037077 | Drug-eluting coronary stents - focus on improved patient outcomes |
Q48028885 | Drug-eluting coronary stents: as safe as bare-metal stents, but optimized antiplatelet therapy may further improve clinical outcome |
Q34091036 | Drug-eluting stents |
Q37874693 | Drug-eluting stents and balloons in peripheral arterial disease: evidence so far. |
Q37577872 | Drug-eluting stents in percutaneous coronary intervention: a benefit-risk assessment |
Q37788985 | Drug-eluting stents in the elderly |
Q24186681 | Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes |
Q24235466 | Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes |
Q37445860 | Drug-eluting stents: a comprehensive appraisal |
Q37141941 | Drug-eluting stents: a review of current evidence on clinical effectiveness and late complications |
Q38162864 | Drug-eluting versus bare-metal coronary stents: where are we now? |
Q31102731 | Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study |
Q28219713 | Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study |
Q35139482 | Effect of imatinib mesylate and rapamycin on the preformed intimal hyperplasia in rat carotid injury model |
Q53517409 | Effect of oxide layer modification of CoCr stent alloys on blood activation and endothelial behavior. |
Q34753360 | Effectiveness of drug-eluting stents versus bare-metal stents in large coronary arteries in patients with acute myocardial infarction |
Q45975445 | Efficacy and safety of a double-coated paclitaxel-eluting coronary stent: the EUCATAX trial. |
Q34319885 | Efficacy and safety of drug-eluting stents in the real world: 8-year follow-up. |
Q45071262 | Emerging Technologies in Flow Diverters and Stents for Cerebrovascular Diseases |
Q46073499 | Everolimus-eluting stents and zotarolimus-eluting stents for percutaneous coronary interventions: two-year outcomes in New York State |
Q44317798 | Evolution of stents: past, present and future |
Q46293725 | Extended follow-up following "full-metal jacket" percutaneous coronary interventions with drug-eluting stents |
Q37016139 | FDA advisory panel on the safety and efficacy of drug-eluting stents: summary of findings and recommendations |
Q42360036 | First-generation paclitaxel- vs. second-generation zotarolimus-eluting stents in small coronary arteries: the BASKET-SMALL Pilot Study |
Q37314517 | Frequency of Vascular Inflammation and Impact on Neointimal Proliferation of Drug Eluting Stents in Porcine Coronary Arteries. |
Q50458420 | Inhibition of restenosis formation without compromising reendothelialization as a potential solution to thrombosis following angioplasty? |
Q38931805 | Inhibitory effects of roscovitine on proliferation and migration of vascular smooth muscle cells in vitro |
Q46093927 | Interoperator and intraoperator (in)accuracy of stent selection based on visual estimation |
Q39651758 | Intractable intraoperative bleeding requiring platelet transfusion during emergent cholecystectomy in a patient with dual antiplatelet therapy after drug-eluting coronary stent implantation (with video). |
Q93646608 | JournalScan |
Q50944358 | Lessons learned in the drug-eluting stent era. |
Q43411274 | Local delivery of sirolimus nanoparticles for the treatment of in-stent restenosis |
Q37765610 | Local drug delivery for treatment of coronary and peripheral artery disease |
Q26767320 | Long-term clinical outcomes of everolimus-eluting stent versus paclitaxel-eluting stent in patients undergoing percutaneous coronary interventions: a meta-analysis |
Q48226488 | Long-term follow-up of the platinum chromium TAXUS Element (ION) stent: The PERSEUS Workhorse and Small Vessel trial five-year results. |
Q39876546 | Low coronary flow velocity and shear stress predict restenosis after sirolimus-eluting stent implantation |
Q37858604 | Low stent thrombosis risk with the XIENCE V® Everolimus-Eluting Coronary Stent: evidence from randomized and single-arm clinical trials |
Q44707694 | Management of multivessel coronary disease: let us not shortchange drug-eluting stents |
Q56638730 | Medikamente freisetzende Koronarstents und mit Medikamenten beschichtete Ballonkatheter |
Q41633062 | Mid-Term Follow-Up of Drug-Eluting Stenting for In-Stent Restenosis: Bare-Metal Stents versus Drug-Eluting Stents |
Q28081589 | Multifaceted prospects of nanocomposites for cardiovascular grafts and stents |
Q41927383 | Multiple sequential complications after sirolimus-eluting stent implantation: very late stent thrombosis, stent fracture, in-stent restenosis, and peri-stent aneurysm |
Q36836467 | Myocardial revascularization: surgery or stenting? |
Q33576893 | Nanomedicine for the reduction of the thrombogenicity of stent coatings. |
Q36654375 | New developments in coronary stent technology |
Q36160441 | New stent design for use in small coronary arteries during percutaneous coronary intervention |
Q37998111 | New technologies aimed at percutaneous intervention in the small coronary artery |
Q37399954 | Nickel-free stainless steel avoids neointima formation following coronary stent implantation |
Q45340209 | Nine-month angiographic and intravascular ultrasound outcomes after resolute zotarolimus-eluting stent implantation for the treatment of in-stent restenosis |
Q37887771 | Nitric oxide: a guardian for vascular grafts? |
Q37269384 | Off-label use of stents: bare-metal versus drug-eluting stents |
Q36614131 | Off-label use: an industry perspective on expanding use beyond approved indications |
Q44305034 | One-year clinical outcome of a randomized trial of polymer-free paclitaxel-eluting stents versus biodegradable polymer-based rapamycin-eluting stents in patients with coronary heart disease |
Q40080241 | One-year outcome of small-vessel disease treated with sirolimus-eluting stents: a subgroup analysis of the e-SELECT registry |
Q37851899 | Optical coherence tomography endpoints in stent clinical investigations: strut coverage |
Q37522553 | Organ transplantation and drug eluting stents: Perioperative challenges |
Q36942534 | Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis |
Q35354402 | Outcomes of small coronary artery stenting with bare-metal stents versus drug-eluting stents: results from the NHLBI Dynamic Registry |
Q36154232 | Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials. |
Q36614116 | Overview of pharmacology and clinical trials program with the zotarolimus-eluting endeavor stent |
Q42548668 | Paclitaxel-Coated Balloons: Investigation of Drug Transfer in Healthy and Atherosclerotic Arteries - First Experimental Results in Rabbits at Low Inflation Pressure |
Q44130145 | Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis |
Q37608478 | Paclitaxel-eluting stents |
Q37878377 | Pathogenesis of implant-associated infection: the role of the host |
Q37629184 | Percutaneous Coronary Intervention: Safety of Methotrexate and Its Possible Benefits on Restenosis After Bare-Metal Stent Deployment |
Q37786640 | Percutaneous coronary intervention for small-vessel coronary disease: highlight on the everolimus-eluting stent |
Q37720739 | Percutaneous coronary intervention using a full metal jacket with drug-eluting stents: major adverse cardiac events at one year |
Q38084549 | Perioperative management of antiplatelet therapy in patients with drug-eluting stents. |
Q37782048 | Periprocedural Myocardial Infarction: Review and Classification |
Q38241974 | Pharmacological inhibition of coronary restenosis: systemic and local approaches |
Q37756979 | Pharmacological prevention and management of restenosis |
Q40099411 | Planned versus provisional rotational atherectomy for severe calcified coronary lesions: Insights From the ROTATE multi-center registry |
Q53494401 | Predictors of coronary artery aneurysm after stent implantation in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. |
Q41486571 | Predictors of diffuse-type in-stent restenosis following drug-eluting stent implantation |
Q43046171 | Procedure-related myonecrosis after bare and drug-eluting stent implantation |
Q36684479 | Promoting vascular regeneration as an alternative to conventional angioplasty-based intervention |
Q47914004 | Prospective randomized trial comparing a nitinol self-expanding coronary stent with low-pressure dilatation and a high-pressure balloon expandable bare metal stent |
Q45398663 | Racial differences in long-term outcomes after percutaneous coronary intervention with paclitaxel-eluting coronary stents |
Q38634385 | Real-Time Electrical Bioimpedance Characterization of Neointimal Tissue for Stent Applications. |
Q47217489 | Restenosis in coronary bare metal stents. Importance of time to follow-up: a comparison of coronary angiograms 6 months and 4 years after implantation |
Q36486769 | Restenosis related to percutaneous coronary intervention has been solved? |
Q37373342 | Retractable-needle catheters: an update on local drug delivery in coronary interventions |
Q37244760 | Revascularization treatment recommendations based on atherosclerotic disease distribution: coronary artery bypass grafting versus stenting |
Q36759494 | Review of the TAXUS Liberté SR paclitaxel-eluting coronary stent |
Q92792658 | Safety and Efficacy of a New Ultrathin Sirolimus-Eluting Stent with Abluminal Biodegradable Polymer in Real-World Practice |
Q41834012 | Safety and efficacy of a non-polymeric paclitaxel-eluting microporous stent in real-world percutaneous coronary intervention |
Q37044202 | Safety and efficacy of a novel iopromide-based paclitaxel-eluting balloon following bare metal stent implantation in rabbit aorta abdominalis |
Q46529943 | Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials |
Q57730945 | Safety of drug-coated stents |
Q37139276 | Safety of drug-eluting stents |
Q51310341 | Same or Different Drug-Eluting Stent Re-Implantation for Drug-Eluting Stent Restenosis: An Assessment Including Second-Generation Drug-Eluting Stents. |
Q34662245 | Second- versus first-generation drug-eluting stents for diabetic patients: a meta-analysis |
Q48200963 | Selection of composite binary endpoints in clinical trials |
Q41488676 | Sensor to detect endothelialization on an active coronary stent |
Q47433386 | Short-term follow-up results of drug-eluting stenting in premature coronary artery disease patients with multiple atherosclerotic risk factors |
Q35707420 | Sirolimus-eluting dextran and polyglutamic acid hybrid coatings on AZ31 for stent applications. |
Q37807873 | Small coronary vessel angioplasty: outcomes and technical considerations |
Q34134537 | Smooth muscle cell-specific insulin-like growth factor-1 overexpression in Apoe-/- mice does not alter atherosclerotic plaque burden but increases features of plaque stability |
Q41962888 | Stent thrombosis: incidence, predictors and new technologies |
Q37691815 | Surface modification of a polyhedral oligomeric silsesquioxane poly(carbonate-urea) urethane (POSS-PCU) nanocomposite polymer as a stent coating for enhanced capture of endothelial progenitor cells. |
Q41848327 | Surgical treatment for coronary artery aneurysm: a single-centre experience |
Q33553921 | Survival advantage in Medicare patients receiving drug-eluting stents compared with bare metal stents: real or artefactual? |
Q52718141 | TAK-733 inhibits inflammatory neointimal formation by suppressing proliferation, migration, and inflammation in vitro and in vivo. |
Q36117819 | The Food and Drug Administration and pragmatic clinical trials of marketed medical products |
Q38310049 | The everolimus-eluting Xience stent in small vessel disease: bench, clinical, and pathology view |
Q36225762 | The power prior: theory and applications |
Q28200757 | The safety and efficacy of aspirin and clopidogrel as a combination treatment in patients with coronary heart disease |
Q40097851 | Thrombosis after stent implantation: how much of a problem is there? |
Q57130197 | Towards a self-reporting coronary artery stent—Measuring neointimal growth associated with in-stent restenosis using electrical impedance techniques |
Q51054146 | Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. |
Q40534372 | Treatment of drug-eluting stent restenosis: Comparison between drug-eluting balloon versus second-generation drug-eluting stents from a retrospective observational study |
Q38376537 | Treatment of small coronary arteries with a paclitaxel-coated balloon catheter |
Q42853401 | Two-year clinical outcomes after large coronary stent (4.0 mm) placement: comparison of bare-metal stent versus drug-eluting stent. |
Q49934946 | Two-year results after coronary stenting of small vessels in Japanese population using 2.25-mm diameter sirolimus-eluting stent with bioresorbable polymer: primary and long-term outcomes of CENTURY JSV study. |
Q46405787 | Two-year safety and effectiveness of the platinum chromium everolimus-eluting stent for the treatment of small vessels and longer lesions |
Q38558645 | Understanding the Outcome of Randomized Trials with Drug-Eluting Stents and Coronary Artery Bypass Graft in Patients with Multivessel Disease: A Review of a 25-Year Journey |
Q47133703 | Undesired Outcomes of the Catania Stent Compared to the Xience Stent in Patients Undergoing Angioplasty: A Double-Blind Randomized Controlled Trial |
Q36985317 | Update on stents: recent studies on the TAXUS stent system in small vessels. |
Q33571243 | Update on the everolimus-eluting coronary stent system: results and implications from the SPIRIT clinical trial program. |
Q38864003 | Usage patterns and 1-year outcomes with the TAXUS Liberté stent: results of the TAXUS OLYMPIA registry |
Q53971688 | Utility of drug-eluting stents in complex lesions and high-risk patients. |
Q37472070 | Xience V everolimus-eluting coronary stent |
Q83901875 | [New developments in drug-eluting stents] |
Search more.